VanEck has just announced the launch of the first ETF in Europe to target bionic engineering in the healthcare industry. The VanEck Bionic Engineering UCITS ETF (CYBO) is now available for trade on the London Stock Exchange and Deutsche Boerse with an expense ratio of 0.55%. As the name suggests, CYBO will track the MVIS Global Bionic Healthcare ESG index that gives exposure to the 25 biggest liquid companies in medical, dental/visual implants, prosthetics, and bioprinting. CYBO’s three largest positions are, Dexcom, Stryker, and Edwards Lifesciences.
ETF Newz Says:
The index blacklists companies that “very severely violate” the UN Global Compact Principles or those that receive revenue from controversial weapons, fossil fuels, nuclear power, oil sands, military equipment, and tobacco.